Patent · US Active

Use of GLP-1 receptor agonists for the treatment of short bowel syndrome

US8236760B2 · kind B2 · utility

15Cited by

3References

17Claims

0Family size

Assignee

Cedars Sinai Medical Center · US

Inventors

Mark Pimentel · Los Angeles, US
Edy E. Soffer · Los Angeles, US
Jeffrey Conklin · Boston, US

Key dates

Filing date	Apr 24, 2008
Grant date	Aug 7, 2012
Priority date	—
Expiry date	Apr 24, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P1/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention describes the methods of using incretin mimetics such as GLP-1 receptor agonists, particularly exenatide, to treat short bowel syndrome and spastic or hyperactive esophageal motor disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.